title: [Effect of the raloxifene versus combined hormonal therapy on the mammary density].
abstract: OBJECTIVE
  to compare in postmenopausal women with osteoporosis or osteopenia the effect of hydrochlorate of raloxifene versus hormone replacement therapy on the mammary density.
  
  
  METHODS
  a double blind, randomized clinical trial was conducted in 57 postmenopausal women older than 55 years with osteoporosis or osteopenia. Participants were randomly allocated in two groups: the intervention group (IG) received hydrochlorate of raloxifene and the control group (CG) received hormone replacement therapy during 6 months. A mammography to evaluate the change of the mammary density, according to the BIRADS criteria, was made before and after the treatment.
  
  
  RESULTS
  twenty-eight patients received hormone replacement therapy and 29 hydrochlorate of raloxifene. Eight (28.5 %) patients of the IG and one (3.0 %) of the CG showed an increased mammary density; whereas in none of IG patients and in four (13.7%) of the CG, the mammary density decreased (p = 0.01).
  
  
  CONCLUSIONS
  the hydrochlorate of raloxifene in postmenopausal women with osteoporosis or osteopenia does not increase the mammary density.
authors.affiliation: Facultad de Medicina de León, Universidad de Guanajuato, Unidad de Investigación en Epidemiología Clínica, IMSS, Guanajuato. blinares@salud.gob.mx
authors.forename: Benigno
authors.initials: B
authors.lastname: Linares-Segovia
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Rodríguez-Osorio
authors.forename: Germán
authors.initials: G
authors.lastname: Storms-Salas
authors.forename: Enrique
authors.initials: E
authors.lastname: Cervantes-Villarreal
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D042361:Mammary Glands, Human / Q000033:anatomy & histology / Q000187:drug effects* / Q000473:pathology; D008875:Middle Aged; D016017:Odds Ratio; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
chemical_list: D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride